{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:31:09Z","timestamp":1780396269773,"version":"3.54.1"},"reference-count":94,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To determine the benefits and harms of nonsteroidal antiinflammatory drugs (NSAID) in axial spondyloarthritis (axSpA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>Systematic review using Cochrane Collaboration methodology. Inclusion criteria: randomized controlled trials (RCT) and quasi-RCT (to June 2014), investigating NSAID versus any control for axSpA, and observational studies of longterm effects (\u2265 6 mos) of NSAID on radiographic progression or adverse events. Main outcomes were pain, Bath Ankylosing Spondylitis Disease Activity Index, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Metrology Index, radiographic progression, number of withdrawals because of adverse events, and number of serious adverse events. Risk of bias was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Thirty-five RCT, 2 quasi-RCT, and 2 cohort studies were included. Twenty-nine RCT and 2 quasi-RCT (n = 4356) were included in pooled analyses [traditional NSAID vs placebo (n = 5), cyclooxygenase-2 (COX-2) vs placebo (n = 3), COX-2 vs traditional NSAID (n = 4), NSAID vs NSAID (n = 24), naproxen vs other NSAID (n = 3), and low- vs high-dose NSAID (n = 5)]. Compared with placebo, both traditional and COX-2 NSAID were consistently more efficacious at 6 weeks and equally safe after 12 weeks. No significant differences in benefits or harms between the 2 NSAID classes and no important differences in benefits or withdrawals because of adverse events between different NSAID were found, especially if studies with high risk of bias were excluded. Single studies suggest NSAID may retard radiographic progression, especially by continuous rather than on-demand NSAID use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>High-quality evidence indicates that both traditional and COX-2 NSAID are efficacious for treating axSpA, and harms are not different from placebo in the short term. Various NSAID are equally effective.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.150721","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T03:15:27Z","timestamp":1454382927000},"page":"607-617","source":"Crossref","is-referenced-by-count":37,"title":["Nonsteroidal Antiinflammatory Drugs for Axial Spondyloarthritis: A Cochrane Review"],"prefix":"10.3899","volume":"43","author":[{"given":"F\u00e9line P.B.","family":"Kroon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart R.A.","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.M.","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Falzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2016,2,1]]},"reference":[{"key":"2018112909352508000_43.3.607.1","first-page":"85","article-title":"[Criteria of the classification of spondylarthropathies]","volume":"57","author":"Amor","year":"1990","journal-title":"Rev Rhum"},{"key":"2018112909352508000_43.3.607.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780341003"},{"key":"2018112909352508000_43.3.607.3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"2","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2018112909352508000_43.3.607.4","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(90)90023-9"},{"key":"2018112909352508000_43.3.607.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780280107"},{"key":"2018112909352508000_43.3.607.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108217"},{"key":"2018112909352508000_43.3.607.7","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"2018112909352508000_43.3.607.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2012.09.003"},{"key":"2018112909352508000_43.3.607.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151027"},{"key":"2018112909352508000_43.3.607.10","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.5.527"},{"key":"2018112909352508000_43.3.607.11","first-page":"6","article-title":"NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal","volume":"28","author":"Fries","year":"1991","journal-title":"J Rheumatol Suppl."},{"key":"2018112909352508000_43.3.607.12","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-10-787"},{"key":"2018112909352508000_43.3.607.13","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-5-359"},{"key":"2018112909352508000_43.3.607.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90185-6"},{"key":"2018112909352508000_43.3.607.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7119.1333"},{"key":"2018112909352508000_43.3.607.16","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199310000-00014"},{"key":"2018112909352508000_43.3.607.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050493"},{"key":"2018112909352508000_43.3.607.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.332.7553.1302"},{"key":"2018112909352508000_43.3.607.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c7086"},{"key":"2018112909352508000_43.3.607.20","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.3.265"},{"key":"2018112909352508000_43.3.607.21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pa.33.040193.002251"},{"key":"2018112909352508000_43.3.607.22","first-page":"CD010952","article-title":"Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)","volume":"7","author":"Kroon","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2018112909352508000_43.3.607.23","unstructured":"Higgins JP Sterne JA . Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions version 510. [Internet. Accessed December 1, 2015.] Available from: handbook.cochrane.org"},{"key":"2018112909352508000_43.3.607.24","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-6-200603210-00010"},{"key":"2018112909352508000_43.3.607.25","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909352508000_43.3.607.26","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909352508000_43.3.607.27","first-page":"1694","article-title":"Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index","volume":"21","author":"Jenkinson","year":"1994","journal-title":"J Rheumatol"},{"key":"2018112909352508000_43.3.607.28","doi-asserted-by":"publisher","DOI":"10.1002\/art.20446"},{"key":"2018112909352508000_43.3.607.29","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.100826"},{"key":"2018112909352508000_43.3.607.30","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F"},{"key":"2018112909352508000_43.3.607.31","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016717"},{"issue":"Suppl 2","key":"2018112909352508000_43.3.607.32","doi-asserted-by":"crossref","first-page":"ii","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2018112909352508000_43.3.607.33","unstructured":"Deeks JJ Altman DG . Analysing data and undertaking meta-analyses: Cochrane handbook for systematic reviews of interventions version 5.1.0. [Internet. Accessed December 1, 2015.] Available from: handbook.cochrane.org"},{"key":"2018112909352508000_43.3.607.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133488"},{"key":"2018112909352508000_43.3.607.35","unstructured":"Sch\u00fcnemann H Higgins J Vist GE Glasziou P Guyatt GH . Presenting results and \u2018summary of findings\u2019 tables. Cochrane handbook for systematic reviews of interventions version 510. [Internet. Accessed December 1, 2015.] Available from: handbook.cochrane.org"},{"key":"2018112909352508000_43.3.607.36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7454.1490"},{"key":"2018112909352508000_43.3.607.37","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200110000-00002"},{"issue":"Suppl 2","key":"2018112909352508000_43.3.607.38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/030006057700502S19","article-title":"A comparative study of Butacote and naproxen in ankylosing spondylitis","volume":"5","author":"Ansell","year":"1977","journal-title":"J Int Med Res"},{"key":"2018112909352508000_43.3.607.39","doi-asserted-by":"publisher","DOI":"10.1136\/ard.37.5.436"},{"key":"2018112909352508000_43.3.607.40","first-page":"70","article-title":"Double-blind, parallel clinical trial of tenoxicam (Ro 12-0068) versus piroxicam in patients with ankylosing spondylitis","volume":"9","author":"Astorga","year":"1987","journal-title":"Eur J Rheumatol Inflamm"},{"key":"2018112909352508000_43.3.607.41","first-page":"1805","article-title":"Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis","volume":"33","author":"Barkhuizen","year":"2006","journal-title":"J Rheumatol"},{"key":"2018112909352508000_43.3.607.42","first-page":"1200","article-title":"The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group","volume":"23","author":"Batlle-Gualda","year":"1996","journal-title":"J Rheumatol"},{"key":"2018112909352508000_43.3.607.43","first-page":"60","article-title":"Retardation of ossification of the lumbar vertebrasl column in ankylosing spondylitis by means of phenylbutazone","volume":"5","author":"Boersma","year":"1976","journal-title":"Scand J Rheumatol"},{"key":"2018112909352508000_43.3.607.44","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90082-3"},{"key":"2018112909352508000_43.3.607.45","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(86)80015-4"},{"key":"2018112909352508000_43.3.607.46","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1979.03300170031022"},{"key":"2018112909352508000_43.3.607.47","first-page":"29","article-title":"A 12-week double-blind study of the efficacy, safety and tolerance of pirazolac b.i.d. compared with indomethacin t.i.d. in patients with ankylosing spondylitis","volume":"16","author":"Carcassi","year":"1990","journal-title":"Drug Exp Clin Res"},{"key":"2018112909352508000_43.3.607.48","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K"},{"key":"2018112909352508000_43.3.607.49","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/38.3.235"},{"key":"2018112909352508000_43.3.607.50","doi-asserted-by":"publisher","DOI":"10.3109\/03009749409103723"},{"key":"2018112909352508000_43.3.607.51","first-page":"660","article-title":"Meclofenamate sodium in the treatment of ankylosing spondylitis. Report of a European double-blind controlled multicenter study","volume":"33","author":"Ebner","year":"1983","journal-title":"Arzneimittelforschung"},{"key":"2018112909352508000_43.3.607.52","doi-asserted-by":"publisher","DOI":"10.1007\/BF02032359"},{"key":"2018112909352508000_43.3.607.53","doi-asserted-by":"publisher","DOI":"10.1185\/03007997709108987"},{"key":"2018112909352508000_43.3.607.54","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029611"},{"key":"2018112909352508000_43.3.607.55","first-page":"597","article-title":"[Treatment of spondylitis ankylosans: Controlled comparative study with tiaprofenic acid and diclofenac]","volume":"80","author":"Heinrichs","year":"1985","journal-title":"Med Klin"},{"key":"2018112909352508000_43.3.607.56","doi-asserted-by":"crossref","unstructured":"Jessop JD . Double-blind study of ketoprofen and phenylbutazone in ankylosing spondylitis. Rheumatol Rehabil 1976;Suppl:37\u201342.","DOI":"10.1093\/rheumatology\/15.5.37"},{"key":"2018112909352508000_43.3.607.57","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(85)80016-0"},{"key":"2018112909352508000_43.3.607.58","first-page":"118","article-title":"A double blind comparison of diclofenac and indomethacin in the treatment of ankylosing spondylitis","volume":"14","author":"Khan","year":"1987","journal-title":"J Rheumatol"},{"key":"2018112909352508000_43.3.607.59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201370"},{"key":"2018112909352508000_43.3.607.60","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/23.1.52"},{"key":"2018112909352508000_43.3.607.61","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90129-4"},{"key":"2018112909352508000_43.3.607.62","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0002-9343(86)90128-2","article-title":"Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with phenylbutazone","volume":"80","author":"Lomen","year":"1986","journal-title":"Am J Med"},{"key":"2018112909352508000_43.3.607.63","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-197708000-00014"},{"key":"2018112909352508000_43.3.607.64","doi-asserted-by":"publisher","DOI":"10.1007\/BF00607674"},{"key":"2018112909352508000_43.3.607.65","first-page":"2619","article-title":"[Ketoprofen in ankylosing spondylitis]","volume":"35","author":"Muller-Fassbender","year":"1985","journal-title":"Therapiewoche"},{"key":"2018112909352508000_43.3.607.66","first-page":"1485","article-title":"[Comparison of naproxen and piroxicam in rheumatoid arthritis and Bechterew\u2019s syndrome. A double-blind parallel multicenter study]","volume":"106","author":"Myklebust","year":"1986","journal-title":"Tidsskr Nor Laegeforen"},{"key":"2018112909352508000_43.3.607.67","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/19.3.193"},{"key":"2018112909352508000_43.3.607.68","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/03009747809095674","article-title":"Proquazone (Biarison) and indomethacin (Indocid) in the treatment of ankylosing spondylitis. Two comparative, clinical, double-blind studies","volume":"21","author":"Nissil\u00e4","year":"1978","journal-title":"Scand J Rheumatol Suppl"},{"key":"2018112909352508000_43.3.607.69","first-page":"23","article-title":"A comparative study of nabumetone and indomethacin in ankylosing spondylitis","volume":"11","author":"Palferman","year":"1991","journal-title":"Eur J Rheumatol Infl"},{"key":"2018112909352508000_43.3.607.70","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(05)80777-5"},{"key":"2018112909352508000_43.3.607.71","first-page":"102","article-title":"NSAIDs retard radiographic spinal progression over two years in ankylosing spondylitis but not in non-radiographic axial spondyloarthritis","volume":"70","author":"Poddubnyy","year":"2011","journal-title":"Z Rheumatol"},{"key":"2018112909352508000_43.3.607.72","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201252"},{"key":"2018112909352508000_43.3.607.73","first-page":"1","article-title":"Tolfenamic acid in ankylosing spondylarthritis: a double-blind comparison to indomethacin","volume":"36","author":"Rejholec","year":"1980","journal-title":"Scand J Rheumatol Suppl"},{"key":"2018112909352508000_43.3.607.74","doi-asserted-by":"publisher","DOI":"10.1177\/030006058801600210"},{"key":"2018112909352508000_43.3.607.75","doi-asserted-by":"publisher","DOI":"10.1185\/03007999009112691"},{"key":"2018112909352508000_43.3.607.76","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075309"},{"key":"2018112909352508000_43.3.607.77","doi-asserted-by":"crossref","unstructured":"Simpson MR Simpson NR Scott BO Beatty DC . A controlled study of flufenamic acid in ankylosing spondylitis. A preliminary report. Ann Phys Med 1966;Suppl:126\u20138.","DOI":"10.1093\/rheumatology\/VIII.suppl_1.126"},{"key":"2018112909352508000_43.3.607.78","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1742-1241.1981.tb08215.x","article-title":"Comparison of piroxicam with indomethacin in ankylosing spondylitis: a double-blind crossover trial","volume":"35","author":"Sydnes","year":"1981","journal-title":"Brit J Clin Pract"},{"key":"2018112909352508000_43.3.607.79","first-page":"426","article-title":"A double blind multicenter trial comparing piroxicam and indomethacin in ankylosing spondylitis with long-term follow-up","volume":"36","author":"Tannenbaum","year":"1984","journal-title":"Curr Ther Res Clin Exp"},{"key":"2018112909352508000_43.3.607.80","doi-asserted-by":"publisher","DOI":"10.1002\/art.20985"},{"key":"2018112909352508000_43.3.607.81","first-page":"1194","article-title":"Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis","volume":"23","author":"Villa Alc\u00e1zar","year":"1996","journal-title":"J Rheumatol"},{"key":"2018112909352508000_43.3.607.82","doi-asserted-by":"publisher","DOI":"10.1002\/art.21054"},{"key":"2018112909352508000_43.3.607.83","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq078"},{"key":"2018112909352508000_43.3.607.84","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes066"},{"key":"2018112909352508000_43.3.607.85","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041129"},{"key":"2018112909352508000_43.3.607.86","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60673-3"},{"key":"2018112909352508000_43.3.607.87","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)02332-6"},{"key":"2018112909352508000_43.3.607.88","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.10.1247"},{"key":"2018112909352508000_43.3.607.89","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1921"},{"key":"2018112909352508000_43.3.607.90","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201244"},{"key":"2018112909352508000_43.3.607.91","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60900-9"},{"key":"2018112909352508000_43.3.607.92","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205178"},{"key":"2018112909352508000_43.3.607.93","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.124206"},{"key":"2018112909352508000_43.3.607.94","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.150037"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.150721","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T18:17:15Z","timestamp":1692209835000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.150721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,1]]},"references-count":94,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,1]]},"published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.3899\/jrheum.150721"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.150721","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,1]]}}}